Endovascular Versus Open Repair of the Common Femoral Artery (TECCO)
Endovascular Versus Open Repair of the Common Femoral Artery: a Randomized Trial (TECCO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Amiens, France
- University Hospital
-
Besançon, France
- University Hospital
-
Bordeaux, France
- University Hospital
-
Clermont-Ferrand, France
- University Hospital
-
Dijon, France
- University Hospital
-
Lyon, France
- University Hospital
-
Marseille, France
- University Hospital
-
Nantes, France
- University Hospital
-
Nantes, France
- NCN Clinic
-
Nantes, France
- St Augustin Clinic
-
Nice, France
- University Hospital
-
Paris, France
- University Hospital, HEGP
-
Paris, France
- University Hospital, Henri Mondor
-
Rouen, France
- University Hospital
-
Saint-Etienne, France
- University Hospital
-
Strasbourg, France
- University Hospital
-
Villeurbanne, France
- Tonkin Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 40 and 90 years-old
- De novo atheromatous common femoral artery stenosis
- Symptomatic lesions (Rutherford stages 3, 4, 5 and 6)
- Haemodynamically significant lesion
- Written informed consent
Exclusion Criteria:
- Restenosis
- Non-atheromatous lesions (dysplasia, post-traumatic, inflammatory)
- external iliac thrombosis and / or common femoral side to treat
- Contraindication to open surgery or endovascular treatment
- Contraindication to anesthesia
- Indication of aorto-femoral, ilio-femoral, femoral-popliteal or femoro-tibialis bypass to associate with the common femoral revascularization
- Indication of a surgical approach to the external iliac artery through a retroperitoneal
- Asymptomatic lesions
- Life expectancy less than one year
- Refusing patient
- Inability to monitor during the test period
- Participation in another clinical trial
- Pregnant Women
- No written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Endovascular treatment
|
A direct stenting will be performed.
|
|
Active Comparator: Open repair treatment
|
The surgeon will perform its usual technique to revascularize the common femoral artery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Morbid-mortality rate at 30 days
Time Frame: 30 days
|
Morbid-mortality rate is defined by: Death, general complications and local complications requiring re-admission and / or reoperation.
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Target lesion revascularization
Time Frame: 6 months
|
6 months
|
|
Target lesion revascularization
Time Frame: 12 months
|
12 months
|
|
Technical success
Time Frame: 1 month
|
1 month
|
|
Hospital length of stay
Time Frame: 1 month
|
1 month
|
|
Primary sustained clinical improvement
Time Frame: 1 month
|
1 month
|
|
Primary sustained clinical improvement
Time Frame: 6 months
|
6 months
|
|
Primary sustained clinical improvement
Time Frame: 12 months
|
12 months
|
|
Primary sustained clinical improvement
Time Frame: 24 months
|
24 months
|
|
Target lesion revascularization
Time Frame: 1 month
|
1 month
|
|
Target lesion revascularization
Time Frame: 24 months
|
24 months
|
|
In-stent restenosis
Time Frame: 1 month
|
1 month
|
|
In-stent restenosis
Time Frame: 6 months
|
6 months
|
|
In-stent restenosis
Time Frame: 12 months
|
12 months
|
|
In-stent restenosis
Time Frame: 24 months
|
24 months
|
|
Stent fracture
Time Frame: 1 month
|
1 month
|
|
Stent fracture
Time Frame: 6 months
|
6 months
|
|
Stent fracture
Time Frame: 12 months
|
12 months
|
|
Stent fracture
Time Frame: 24 months
|
24 months
|
|
Secondary sustained clinical improvement
Time Frame: 1 month
|
1 month
|
|
Secondary sustained clinical improvement
Time Frame: 6 months
|
6 months
|
|
Secondary sustained clinical improvement
Time Frame: 12 months
|
12 months
|
|
Secondary sustained clinical improvement
Time Frame: 24 months
|
24 months
|
|
Target extremity revascularization
Time Frame: 1 month
|
1 month
|
|
Target extremity revascularization
Time Frame: 6 months
|
6 months
|
|
Target extremity revascularization
Time Frame: 12 months
|
12 months
|
|
Target extremity revascularization
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yann GOUEFFIC, Doctor, Nantes university hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BRD/10/06-Q
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.